Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
about
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoChemotherapy for downstaging unresectable liver metastases from colorectal cancerPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusMolecular origins of cancer: Molecular basis of colorectal cancerMolecular Subtypes and Personalized Therapy in Metastatic Colorectal CancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesThe mutational landscape of hepatocellular carcinomaNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Identification of aberrant pathways and network activities from high-throughput dataRecent applications of chemosensitivity tests for colorectal cancer treatmentMolecular alterations and biomarkers in colorectal cancerEGFR/HER-targeted therapeutics in ovarian cancerPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesMolecular pathology of lung cancer: key to personalized medicine.Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new eraBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Mechanisms of resistance to anti-EGFR therapy in colorectal cancerGenetics and Genetic Biomarkers in Sporadic Colorectal CancerExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer DevelopmentKRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyPhase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancerColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachWhere now for anti-EGF receptor therapies in colorectal cancer?Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis.C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2.Proteomics, morphoproteomics, saliva and breast cancer: an emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response.K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma.Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
P2860
Q21245712-32381756-7172-479A-9FEB-1FC04388E836Q24234615-D25FEB98-2CAE-4561-BBBE-F5162496FFDBQ24289005-37BAFBFD-0E31-4B4E-B7BE-D3DD4DD7710AQ24600932-F8F828A1-889B-4016-8265-AD0188D2F66EQ24617331-0EF7A981-D689-4792-85FA-3FAD21F8D0C5Q26747329-509DC809-609C-43C5-A0D5-7C993C9BFA0CQ26766535-DFA2CEF3-8385-4D69-919B-075467F2E134Q26768427-EC6B3647-057B-4E9F-B229-7720A76E528AQ26777478-238BD9E2-A872-4019-840C-8A44110EC099Q26796348-A7B3C85D-302F-4698-8DA2-00562BBE462CQ26828992-7E1DAC1F-A86F-482B-A53B-0655CC489DFCQ26829854-9C510556-AAB1-42D2-8634-822369FD7AEBQ26851075-70F096BA-5839-47AE-A481-6F64D038B6BAQ26862317-FB06B89A-C767-4C71-96E3-3DA58AA24509Q26863231-5CD89A41-1916-4A96-A1CC-09F4A7560293Q27015224-3EC4C988-2E3F-48E6-A3D7-49BF3163B04AQ27691299-20066DA8-5D32-44B3-BEA7-97DD8DC0F157Q27693248-A6896C41-0C1C-4BED-956D-B5625EE9176BQ27852062-45892488-777B-4A96-AB9E-73C6A786F43FQ27852970-8FFD6AEC-92D4-4D68-A936-6CE5792A2486Q28074073-EE831D93-379C-483A-AB66-7B8E07FED1E4Q28084346-A7F30C3F-72B9-47AC-BC1B-2C9157D57BF9Q28087333-B88C18CD-6CD6-49A0-AB81-766799749ADAQ28115416-45C5C276-6585-4FF6-AFA0-726C772D18F6Q28285473-DA6C169D-C238-4018-BEFA-12109B536257Q28534997-90887EF3-BFEA-4A55-9D4C-4356E4B436CCQ28647615-4F750650-E5EA-4E3D-9D58-0034CF810B78Q31038305-E6EAFFE2-38B2-4AE2-8EF9-9B9030ADDF84Q33352155-11C0F735-B2E9-45ED-912D-E1BBA408F90AQ33394650-A35735B3-B0E6-4288-9F64-659ADF60BEDDQ33526301-7BB6C33D-7A4B-4BC0-ADB6-A67FBDD77648Q33620070-45E99C02-4654-4E0F-9E30-C06C4E6C7995Q33683991-B29EBBB7-CF68-4D35-9A9E-64BAAAE16DAEQ33688535-2102BB0E-6261-441C-9801-09FFEB7AC954Q33694698-758CD9AB-901A-41CF-B8CB-4D8A4F83C291Q33703112-99307541-0EB9-42F9-ABA0-28BC270758C5Q33726858-6C06A310-5061-4A82-B4BC-EDF47D9F27CBQ33745140-D389EB2A-8745-4A76-A680-1E5AB6901124Q33756779-322051A7-EE8F-441A-A058-1F13B837BCB7Q33794086-EA28D55E-4335-4467-85FA-98AC861600B0
P2860
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@en
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@nl
type
label
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@en
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@nl
prefLabel
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@en
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@nl
P2860
P50
P921
P356
P1476
Biomarkers predicting clinical ...... metastatic colorectal cancer.
@en
P2093
Julia Balfour
P2860
P304
P356
10.1093/JNCI/DJP280
P407
P5008
P577
2009-09-08T00:00:00Z
2009-10-07T00:00:00Z